14,767 Shares in 10x Genomics, Inc. (NASDAQ:TXG) Bought by Farringdon Capital Ltd.

Farringdon Capital Ltd. bought a new stake in shares of 10x Genomics, Inc. (NASDAQ:TXG) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 14,767 shares of the company’s stock, valued at approximately $212,000.

Several other large investors also recently made changes to their positions in the stock. HighTower Advisors LLC bought a new position in 10x Genomics in the 3rd quarter worth $430,000. Stifel Financial Corp lifted its position in shares of 10x Genomics by 56.2% during the 3rd quarter. Stifel Financial Corp now owns 16,369 shares of the company’s stock worth $370,000 after purchasing an additional 5,890 shares during the last quarter. State Street Corp boosted its stake in 10x Genomics by 7.1% during the 3rd quarter. State Street Corp now owns 1,750,643 shares of the company’s stock valued at $39,530,000 after purchasing an additional 116,534 shares during the period. Barclays PLC grew its holdings in 10x Genomics by 11.7% in the 3rd quarter. Barclays PLC now owns 602,536 shares of the company’s stock valued at $13,605,000 after buying an additional 63,079 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in 10x Genomics by 2.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,815,710 shares of the company’s stock worth $41,009,000 after buying an additional 42,777 shares during the period. Institutional investors own 84.68% of the company’s stock.

Insider Activity at 10x Genomics

In other news, CEO Serge Saxonov sold 5,092 shares of the company’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $11.07, for a total transaction of $56,368.44. Following the transaction, the chief executive officer now owns 879,482 shares of the company’s stock, valued at $9,735,865.74. This represents a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Benjamin J. Hindson sold 4,573 shares of 10x Genomics stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $50,623.11. Following the completion of the sale, the insider now owns 335,324 shares of the company’s stock, valued at approximately $3,712,036.68. The trade was a 1.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 10.03% of the stock is currently owned by company insiders.

10x Genomics Trading Down 6.5 %

Shares of 10x Genomics stock opened at $7.51 on Friday. The stock has a market capitalization of $918.49 million, a price-to-earnings ratio of -4.94 and a beta of 2.01. The firm’s 50-day moving average price is $9.88 and its two-hundred day moving average price is $13.47. 10x Genomics, Inc. has a 1-year low of $6.78 and a 1-year high of $29.37.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. As a group, equities research analysts predict that 10x Genomics, Inc. will post -1.43 EPS for the current year.

Analyst Upgrades and Downgrades

TXG has been the topic of several research analyst reports. Leerink Partners downgraded shares of 10x Genomics from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $25.00 to $12.00 in a research note on Thursday, February 13th. Citigroup dropped their price objective on shares of 10x Genomics from $20.00 to $15.00 and set a “buy” rating on the stock in a report on Tuesday, March 4th. JPMorgan Chase & Co. decreased their target price on 10x Genomics from $14.00 to $12.00 and set a “neutral” rating on the stock in a research report on Thursday, February 13th. UBS Group cut their price target on 10x Genomics from $20.00 to $14.00 and set a “neutral” rating for the company in a report on Thursday, February 13th. Finally, Leerink Partnrs cut 10x Genomics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 13th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, 10x Genomics has a consensus rating of “Hold” and a consensus price target of $19.79.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.